NAFLD: From Mechanisms to Therapeutic Approaches

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Jul 27

PMID 35885052

Authors

Karim Gariani

Francois R Jornayvaz

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) now represents the most frequent chronic liver disease worldwide [...].

Citing Articles

Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease.

Memaj P, Ouzerara Z, Jornayvaz F Int J Mol Sci. 2023; 24(14).

PMID: 37511031 PMC: 10379080. DOI: 10.3390/ijms241411271.

Non-alcoholic fatty liver disease in type 1 diabetes: Prevalence and pathophysiology.

Memaj P, Jornayvaz F Front Endocrinol (Lausanne). 2022; 13:1031633.

PMID: 36531463 PMC: 9752856. DOI: 10.3389/fendo.2022.1031633.

References

Lima R, Stefano J, de Mello Malta F, Pinho J, Carrilho F, Arrese M . Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. Biomedicines. 2021; 9(12). PMC: 8698380. DOI: 10.3390/biomedicines9121751. View

Kisoh K, Sugahara G, Ogawa Y, Furukawa S, Ishida Y, Okanoue T . Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers. Biomedicines. 2021; 9(11). PMC: 8615377. DOI: 10.3390/biomedicines9111647. View

Mak A, Lee J, Dijk A, Vali Y, Aithal G, Schattenberg J . Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines. 2021; 9(12). PMC: 8698886. DOI: 10.3390/biomedicines9121920. View

Shafiha R, Bahcivanci B, Gkoutos G, Acharjee A . Machine Learning-Based Identification of Potentially Novel Non-Alcoholic Fatty Liver Disease Biomarkers. Biomedicines. 2021; 9(11). PMC: 8615894. DOI: 10.3390/biomedicines9111636. View

Kulkarni A, Ibrahim S, Haider I, Basha A, Montgomery E, Ermis E . A Novel 2-Hit Zebrafish Model to Study Early Pathogenesis of Non-Alcoholic Fatty Liver Disease. Biomedicines. 2022; 10(2). PMC: 8962409. DOI: 10.3390/biomedicines10020479. View

Skat-Rordam J, Ipsen D, Seemann S, Latta M, Lykkesfeldt J, Tveden-Nyborg P . Modelling Nonalcoholic Steatohepatitis In Vivo-A Close Transcriptomic Similarity Supports the Guinea Pig Disease Model. Biomedicines. 2021; 9(9). PMC: 8471870. DOI: 10.3390/biomedicines9091198. View

von Loeffelholz C, Roth J, Coldewey S, Birkenfeld A . The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. Biomedicines. 2021; 9(12). PMC: 8698784. DOI: 10.3390/biomedicines9121853. View

Nasce A, Gariani K, Jornayvaz F, Szanto I . NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. Antioxidants (Basel). 2022; 11(6). PMC: 9219746. DOI: 10.3390/antiox11061131. View

Albadawy R, Agwa S, Khairy E, Saad M, El Touchy N, Othman M . Clinical Significance of HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 RNA Panel in NAFLD/NASH Diagnosis: Egyptian Pilot Study. Biomedicines. 2021; 9(9). PMC: 8472260. DOI: 10.3390/biomedicines9091248. View

10.

Gariani K, Jornayvaz F . Pathophysiology of NASH in endocrine diseases. Endocr Connect. 2021; 10(2):R52-R65. PMC: 7983516. DOI: 10.1530/EC-20-0490. View

11.

Ismaiel A, Jaaouani A, Leucuta D, Popa S, Dumitrascu D . The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver Fibrosis-Systematic Review and Meta-Analysis. Biomedicines. 2021; 9(12). PMC: 8698356. DOI: 10.3390/biomedicines9121890. View